What question did this study set out to answer?

To determine the relationship between clinical biomarkers of cardiomyocyte injury and mortality in cancer patients receiving immune checkpoint inhibitors.

June 1, 2021Journal for ImmunoTherapy of CancerOpen Access

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

View Full Paper

Ask AI

Bookmark

Why the study?

Data are limited on the outcomes and prognostic utility of biomarkers associated with immune checkpoint inhibitor-associated myocarditis.

Key Points

To determine the relationship between clinical biomarkers of cardiomyocyte injury and mortality in cancer patients receiving immune checkpoint inhibitors.
Retrospectively analyzed 23 cancer patients who developed troponin elevations while receiving immune checkpoint inhibitor (ICI) therapy at a comprehensive cancer center.
Obtained serial electrocardiograms, troponin I, and creatine kinase-MB (CK-MB) levels to compare clinical characteristics between survivors and non-survivors.
Higher presentation levels of troponin I (p=0.037) and CK-MB (p=0.034) correlated with progression to severe myocarditis.
Elevated troponin I (p=0.016), total CK (p=0.013), and CK-MB (p=0.034) were significantly associated with increased mortality, while advanced atrioventricular block showed a trend toward increased mortality (p=0.088).
Weekly troponin surveillance led to earlier hospital admission (p=0.022) and faster initiation of corticosteroid therapy (p=0.053), improving patient outcomes.

Population

23 patients developing symptomatic and asymptomatic troponin elevations on ICI therapy at a comprehensive cancer center

Comparison

Survivors vs non-survivors

Design

Retrospective study

Authors

IPIgor PuzanovRoswell Park Comprehensive Cancer Center PSPoornima Subramanian YYYan YatsynovichWright State University

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Elevated troponin I, CK, and CK-MB associate with mortality in ICI myocarditis; supports biomarker monitoring but remains hypothesis-generating without prospective validation.

Cite This Study

Puzanov et al. (2021) studied this question.

synapsesocial.com/papers/6a7101f3febe604dd709bf38 https://doi.org/10.1136/jitc-2021-002553

Topics

Myocarditis

View Full Paper

Ask AI

Bookmark

Implication

Elevated troponin I, CK, and CK-MB associate with mortality in ICI myocarditis; supports biomarker monitoring but remains hypothesis-generating without prospective validation.

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

Key Points

Discussion

Implication

Cite This Study

Topics

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

Key Points

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider